Abiopharma

Collegium Pharmaceutical Inc (COLL) Announces Business Combination Collegium Pharmaceutical Inc (COLL) has entered into a strategic transaction. Transaction Details:

• Target Company: we exclude restructuring expenses from adjusted ebitda. restructuring expenses primarily include employee severance and contract termination costs that are not related to
• Purchase Price: $805
  • Based on continued strength across the Company’s ADHD and pain portfolios, raised full
  • year 2025 financial guidance in November 2025 to be in the range of $775 to $785 million for net revenue with adjusted EBITDA in the range of $460 to $470 million, with annual results expected to be reported in February
  • •In late December, announced the successful closing of a $980 million syndicated credit facility which was used in part to repay the remaining $581 million of principal representing the entire remaining balance of our previous $646 million term loan secured from funds managed by Pharmakon Advisors, LP. The new aggregate credit facility consists of a five